A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy
Source abstract
Abstract
Late detection, peritoneal dissemination, chemoresistance and weak response to targeted therapeutics lead to high mortality in ovarian cancer. More efficient and specific tumor imaging and therapeutic agents are needed to improve the resection rate of surgery and to eliminate residual disease. The expression patterns of follicle-stimulating hormone (FSH) receptor make it a suitable target for ovarian cancer. Here, we report a strategy to develop an organic near-infrared probe for FSH receptor-targeted tumor imaging and photothermal therapy. The FSH-Rh760 probe was conjugated from the Rh760 fluorophore with the FSH β subunit 33-53 peptide. FSH-Rh760 specifically distinguished peritoneal metastatic ovarian cancerous foci from surrounding normal tissues with a high tumor-to-background ratio. The fluorescence signals in tumors peaked at 2 h and were cleared at 120 h postinjection. FSH-Rh760 treatment rapidly increased the abdomen temperature of mice up to ∼43 °C upon exposure to a near-infrared laser and effectively suppressed peritoneal tumor growth with tumor specificity. No significant systemic toxicities were observed. This study demonstrates the targeting ability and biocompatibility of FSH receptor-targeted theranostics and highlights its potential for clinical application in imaging-guided precision tumor resection and photothermal therapy to eliminate cancer lesions intraoperatively and postoperatively.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Ovarian cancer diagnosis and treatment · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Cancer statistics, 202310.3322/caac.21763 ↗
2. Optimizing treatment in recurrent epithelial ovarian cancer10.1080/14737140.2017.1398088 ↗
3. Epithelial ovarian cancer: evolution of management in the era of precision medicine
4. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant10.3389/fimmu.2020.577869 ↗
5. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities10.1016/j.drudis.2023.103666 ↗
6. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer10.3390/cancers9080104 ↗
7. A framework for a personalized surgical approach to ovarian cancer, Nature Reviews
8. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: an NRG Oncology/Gynecologic Oncology Group study10.1016/j.ygyno.2018.03.043 ↗
9. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model10.1016/j.ebiom.2020.102783 ↗
10. Beyond the margins: real-time detection of cancer using targeted fluorophores10.1038/nrclinonc.2016.212 ↗
11. Black‐phosphorus‐incorporated hydrogel as a sprayable and biodegradable photothermal platform for postsurgical treatment of cancer10.1002/advs.201700848 ↗
12. Aggregation-enhanced photophysical performance of D-π-A structured hemicyanine for NIR-II fluorescent and photoacoustic imaging-guided photothermal therapy10.1021/cbmi.2c00004 ↗
13. Recent advances in selective photothermal therapy of tumor10.1186/s12951-021-01080-3 ↗
14. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer10.1039/C8CS00618K ↗
15. Ultrasound‐controlled drug release and drug activation for cancer therapy
16. Dual-stimuli responsive and reversibly activatable theranostic nanoprobe for precision tumor-targeting and fluorescence-guided photothermal therapy10.1038/ncomms14998 ↗
17. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer10.1016/j.ygyno.2019.07.010 ↗
18. Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity10.1158/0008-5472.CAN-16-1454 ↗
19. Magnetic semiconductor Gd-doping CuS nanoparticles as activatable nanoprobes for bimodal imaging and targeted photothermal therapy of gastric tumors10.1021/acs.nanolett.8b04179 ↗
20. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target10.1158/1078-0432.CCR-16-0492 ↗
21. Expression of follicle-stimulating hormone receptor in tumor blood vessels10.1056/NEJMoa1001283 ↗
22. Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells10.1039/C3NR05042D ↗
23. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian CarcinomaIn vivo10.1158/0008-5472.CAN-08-4721 ↗
24. Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy10.1016/j.ygyno.2014.06.030 ↗
25. Reversible ratiometric probe combined with the time-gated method for AccurateIn vivo gastrointestinal pH sensing10.1021/acsami.0c04237 ↗
26. A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH10.1021/bi00457a015 ↗
27. Structure of follicle-stimulating hormone in complex with the entire ectodomain of its receptor10.1073/pnas.1206643109 ↗
28. Follicle-stimulating hormone receptor as a target in the redirected T-cell therapy for cancer10.1158/2326-6066.CIR-15-0047 ↗
29. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
30. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival10.1111/j.1365-2559.2011.03848.x ↗
31. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)10.1186/s13048-016-0300-5 ↗
32. PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging10.1021/mp500766x ↗
33. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism10.1186/s12951-020-00720-4 ↗
34. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results10.1038/nm.2472 ↗
35. A novel tumor-specific agent for intraoperative near-infrared fluorescence imaging: a translational study in healthy volunteers and patients with ovarian cancer10.1158/1078-0432.CCR-15-2640 ↗
36. A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of folate receptor–positive ovarian cancer (study 006)10.1200/JCO.22.00291 ↗
37. The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: a systematic review10.1016/j.ygyno.2021.05.017 ↗
38. Real-time single-walled carbon nanotube-based fluorescence imaging improves survival after debulking surgery in an ovarian cancer model10.1021/acsnano.8b09829 ↗
39. NIR-II Fluorescence imaging for cerebrovascular diseases
40. Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase–activated fluorescent probe10.1126/scitranslmed.3002823 ↗
41. Sensitive beta-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo10.1038/ncomms7463 ↗
42. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials10.1002/cncr.24149 ↗
43. Adjuvant photothermal therapy inhibits local recurrences after breast-conserving surgery with little skin damage10.1021/acsnano.7b07757 ↗
44. Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma10.1038/s41598-018-29018-0 ↗
45. Hyperthermia targeting the tumor microenvironment facilitates immune checkpoint inhibitors10.3389/fimmu.2020.595207 ↗
46. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy10.1038/s41467-019-12771-9 ↗
47. Recent advances in hyperthermia therapy‐based synergistic immunotherapy10.1002/adma.202004788 ↗
48. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
49. Quickly evolving near‐infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment
50. Hydrogenated silicene nanosheet functionalized scaffold enables immuno‐bone remodeling
51. Bandgap‐engineered germanene nanosheets as an efficient photodynamic agent for cancer therapy
52. A multiple-response cascade nanoreactor for starvation and deep catalysis chemodynamic assisted near-infrared-II mild photothermal therapy10.1021/cbmi.2c00003 ↗